(A) AR Huh-BAT cells had significantly higher viabilities at 3 μM of sorafenib, 1 μM of 5-FU, and 10 μM of cisplatin compared to Huh-BAT cells. (B) AR HepG2 cells had significantly higher viabilities at 3 μM of sorafenib and 1 μM of 5-FU compared to HepG2 cells. (C) AR Huh-BAT cells had significantly higher viabilities at concentrations of 3, 5, and 10 μM of sorafenib compared to Huh-BAT cells. (D) AR HepG2 cells had significantly higher viabilities at concentrations of 1, 3, 5, and 10 μM of sorafenib compared to HepG2 cells. (E) Tumor growth rates of AR Huh-BAT cells were significantly higher than those of Huh-BAT cells in xenograft nude mice. *P<0.05; **P<0.01. Abbreviation: AR, anoikis-resistant; sora, sorafenib; 5-FU, 5-fluorouracil.